The last few weeks have been historic in the fight against cancer. Novartis got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech company working in the field. Neither can rest on its laurels. Research in the field is moving so fast that today’s breakthroughs can easily become tomorrow’s has-beens. “I can’t think of any other therapies in oncology that have seen such rapid development,” said Rachel Webster, senior director of oncology at Decision Resources Group, a health care research and consulting firm in London.
NYS Entity Status
NYS Filing Date
APRIL 10, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC NOT-FOR-PROFIT CORPORATION
2014 - EARTHWORKS INSTITUTE, INC.
Around the Web
- Cancer drug research moving fast in immunotherapy field
By Michelle Fay Cortez - Tuesday Sep 5, 2017
- ‘Too Big to Fail’ Label May Shrink for Some Firms Under Trump
By VICTORIA FINKLE - Monday Sep 4, 2017
The Trump administration is examining the use of the designation for large non-bank financial institutions, with a closely anticipated Treasury report on the matter expected next month.
- “It’s Shame On Us If We Blow It”: Highlights From NY Seizes the Momentum
By Ben Fidler - Wednesday Jun 7, 2017
Mike Foley, a drug industry veteran and director of the Tri-Institutional Therapeutics Discovery Institute, has a pointed message for the New York life sciences industry: Don’t waste the moment. Changing the course of New York biotech has been a saga that dates back to the 1990s, and as Xconomy has detailed, progress has been made […]
- Steve Webster leads Made In Denmark tournament; Pieters misses cut
By Associated Press - Friday Aug 25, 2017
FARSO, Denmark — Defending champion Thomas Pieters missed the cut at the Made In Denmark tournament, as Steve Webster took a one-shot lead (...)
- All-Clear for Big Banks Raises Fears of a Return to Risk
By NELSON D. SCHWARTZ - Friday Jun 30, 2017
The Federal Reserve’s passing grade for all 34 institutions, the first all-clear since tests began, will have major consequences. The first: Surging bank stocks.
- The Studio Museum Has a Vision for Its Home. And a Power Player at the Helm.
By ROBIN POGREBIN - Tuesday Sep 26, 2017
Thelma Golden, the museum’s formidable steward, is focused on a big building project and many initiatives at an important time for the institution.